Overview

Phase I Study of Cetuximab in Combination With 5-fluoruracil, Mitomycin C and Radiotherapy in Patients With Anal Cancer Stage T2 (>4 cm) - T4 N0-3 M0 or Any T N2-3 M0

Status:
Completed

Trial end date:
2020-01-01

Target enrollment:

Participant gender:

Summary

- To establish maximum tolerated dose of the two cytotoxic drugs 5-fluoruracil and mitomycin C when given together with the antibody cetuximab in patients with locally advanced cancer in the anal region - To evaluate acute toxicity - To evaluate late toxicity - To evaluate response rate - To evaluate recurrence free survival - To evaluate overall survival

Phase:

Phase 1

Details

Lead Sponsor:

Lund University Hospital

Collaborator:

Merck Sharp & Dohme Corp.

Treatments:

Cetuximab
Fluorouracil
Mitomycin
Mitomycins